PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services
CompanyDeals

PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia
CompanyDrug

Rona Therapeutics Initiates Phase II Study for RN0361 in Severe Hypertriglyceridemia

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis
CompanyDrug

Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-6213 in Solid Tumor Diagnosis

Alphamab Oncology's JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer
CompanyDrug

Alphamab Oncology’s JSKN033 Receives Breakthrough Therapy Designation for Platinum Resistant Ovarian Cancer

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio
CompanyDeals

AstraZeneca to Acquire EsoBiotec for Up to $1 Billion to Boost Cell Therapy Portfolio

AstraZeneca Licenses Alteogen's ALT-B4 for Subcutaneous Cancer Therapies
CompanyDeals

AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies

Merck & Co.'s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan
CompanyDrug

Merck & Co.’s Winrevair Approved for Pulmonary Arterial Hypertension in Hainan

Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment
CompanyDrug

Visirna Therapeutics Announces Positive Phase III Results for Plozasiran in FCS Treatment

ROBO Medical's Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval
CompanyMedical Device

ROBO Medical’s Innovative Gastrointestinal Endoscopic Instrument Gains NMPA Approval

Basilea Pharmaceutica Cresemba Asia Pacific Sales
CompanyDeals

Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific

Phenomenex Inaugurates China R&D Center to Advance Danaher's "Launching China" Strategy
Company

Phenomenex Inaugurates China R&D Center to Advance Danaher’s “Launching China” Strategy

BMS's Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma
CompanyDrug

BMS’s Breyanzi Approved by EC for Relapsed or Refractory Follicular Lymphoma